Cancer Myth in the News: Antiperspirant and Breast Cancer Claims

Where this claim started

The claim shows up every few months. It says the aluminum in antiperspirant soaks into the skin, builds up in breast tissue, and starts cancer. Some versions add that shaving lets more of it in.

The idea is not random. Antiperspirant goes on skin that sits close to the breast. Aluminum salts are the active part. In a lab dish, some aluminum compounds act a little like estrogen, and estrogen can help some breast cancers grow. So the story sounds like it fits.

The National Cancer Institute has looked at this. Its answer is short. No scientific evidence links these products to breast cancer.

What the studies actually found

Only a few studies have ever asked the question directly.

A 2002 study interviewed 813 women with breast cancer and 793 women without it. It found no rise in risk among women who used an underarm antiperspirant or deodorant. It also found no rise among women who shaved with a blade razor and used the product within an hour.

A smaller 2006 study, with 54 women with breast cancer and 50 without, also found no link.

One 2003 study of 437 breast cancer survivors did report a younger age at diagnosis among frequent users. That study looked backward, and asked women to recall habits from years earlier. Recall is a weak tool. The authors did not treat the finding as proof, and neither should we.

NCI also notes that a 2014 review found no clear evidence that aluminum in these products raises risk. Parabens are a separate worry in the same story. They have been found in breast tumor tissue. Nothing shows they cause the tumor. Most US antiperspirants no longer contain them. We go deeper into the chemistry in our piece on whether deodorant causes breast cancer.

What does move breast cancer risk

The risk factors with real weight are less catchy. Age is the biggest one. Others include a family history, an inherited BRCA1 or BRCA2 gene change, dense breast tissue, alcohol, obesity after menopause, hormone therapy, an early first period, a late menopause, and past radiation to the chest.

Between 5 and 10 percent of women with breast cancer carry an inherited BRCA1 or BRCA2 change. In those women, lifetime risk runs far higher than average.

None of these are a product on a shelf. That is the point. Time spent on the underarm claim is time not spent on screening.

When to get checked

The Task Force that sets US screening advice now says women should have a mammogram every other year, from age 40 through 74. A mammogram is an X-ray of the breast. Our guide to what a mammogram involves walks through the visit itself.

Screening is for people with no symptoms. Symptoms are a separate track. Call your clinician within a week or two for:

• A new lump or thick patch in the breast or armpit
• Skin that dimples, puckers, or looks like orange peel
• A nipple that turns in, or new scaling and crusting
• Clear or bloody fluid from one nipple, with no squeezing
• Redness, warmth, and swelling in one breast that does not settle

Most lumps are not cancer. Cysts, fibroadenomas, fat necrosis, and duct problems all cause lumps. But a lump gets checked, not watched from home. Knowing your own normal is the point of breast awareness.

How a breast change gets worked up

The first step is imaging. That means a mammogram, an ultrasound, and sometimes an MRI. If the image looks off, the next step is a biopsy. A biopsy takes a small piece of tissue through a needle so a pathologist can look at it.

Only the biopsy can say cancer or not. Staging follows. Stage describes how far the cancer has gone. Doctors check the tumor size, whether lymph nodes under the arm hold cancer cells, and whether it has spread further.

The lab also tests the tissue for estrogen and progesterone receptors and for HER2, a growth protein. Those results steer treatment more than the stage alone.

What happens after a diagnosis

Most people have surgery. That is either a lumpectomy, which removes the lump and a rim of tissue, or a mastectomy, which removes the breast. Nodes under the arm are usually sampled at the same time.

Radiation often follows a lumpectomy. Drug treatment depends on the receptor results. Hormone-blocking pills are used for receptor-positive disease, often for five years or more. HER2-positive disease gets antibody drugs. Chemotherapy is added when the risk of return is high.

A callback after a screening mammogram is common and usually ends with normal results. We cover what a callback means in more detail.

What the numbers say, and about whom

These are group numbers from the SEER program. They describe a large population. They do not describe you.

For female breast cancer, five-year relative survival is 91.9 percent for cases from 2016 to 2022. Stage matters a great deal. When the cancer is still in the breast, that figure is 100.0 percent. When it has reached nearby nodes, it is 87.5 percent. When it has spread to distant organs, it is 33.8 percent.

About 64 percent of cases in that 2016–2022 window are found while still confined to the breast. Median age at diagnosis is 64.

Sources

• NCI, Antiperspirants/Deodorants and Breast Cancer — https://www.cancer.gov/about-cancer/causes-prevention/risk/myths/antiperspirants-fact-sheet
• NCI, Common Cancer Myths and Misconceptions — https://www.cancer.gov/about-cancer/causes-prevention/risk/myths
• NCI, Breast Changes and Conditions — https://www.cancer.gov/types/breast/breast-changes
• NCI PDQ, Breast Cancer Treatment (Health Professional Version) — https://www.cancer.gov/types/breast/hp/breast-treatment-pdq
• SEER Cancer Stat Facts, Female Breast Cancer — https://seer.cancer.gov/statfacts/html/breast.html
• USPSTF, Breast Cancer: Screening — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening